Zinc is an essential micro-nutrient that participates in catalytic and structural functions touching nearly
every metabolic process in the cell. While alterations in neuronal Zn2+ distribution have been associated
with multiple disease states including Alzheimer’s Disease (AD), ALS, schizophrenia, and depression,
the molecular mechanism of Zn2+ homeostasis in neurons is largely unexplored. The Zinc and Iron-reg-
ulated transport Proteins (ZIP) mediate the entrance of first row transition metals into the cytoplasm.
hZIP12, one of the fourteen human ZIPs, is a Zn2+ uptake transporter expressed in the brain. hZIP12
cSNPs (coding single nucleotide polymorphisms) have been associated with AD and abnormalities in the
caudate nucleus. Importantly, our previous structural functional studies of the homologous hZIP4 enables
postulation of the likely functional alteration introduced by observed cSNP. This proposal is based on the
hypothesis that studies of hZIP12 and variants associated with neurodegenerative diseases will serve as
an entrance point to build testable mechanistic models of neuronal Zn2+ homeostasis. Aim one tests the
hypothesis that hZIP12 mutations associated with neuronal diseases impact transport activity and/or sur-
face expression. hZIP12-mediated Zn2+ transport will be measured in neuronal SH-SY5Y cells expressing
wild type and mutated proteins. Membrane targeting and dimerization studies will characterize predicted
structural effects of observed cSNPs. The structural and functional consequence of three types of vari-
ants will be examined: 1) one cSNP linked to AD, 2) two cSNPs associated with morphological alterations
of the caudate nucleus; and 3) two cSNPs hypothesized to alter metal selectivity. Aim two tests the hy-
pothesis that hZIP12 dysfunction modifies cellular Zn2+ pools and metal distribution. Cytosolic Zn2+ levels,
as well as transmembrane transporter expression, will be assessed under early steady state and non-
toxic Zn2+ levels. To this end, targeted as well as unbiased global approaches will be employed: 1) size
exclusion chromatography-inductively coupled plasma mass spectrometry (SEC-ICP-MS) profiling of the
proteome will be combined with mass spectrometry (LC-MS/MS) to identify Zn2+ binding proteins. 2) The
expression of compensatory genes participating in the response will be evaluated via unbiased
approaches (RNA-Seq) as well as directed Q-PCR of genes known to be involved in Zn2+
homeostasis/distribution. Results from these studies will initiate the definition of molecular and
subcellular mechanisms of Zn2+ homeostasis in the brain, provide a detailed description of hZIP12
function in neuronal Zn2+ subcellular distribution, and elucidate the role of hZIP12 in relevant
neurodegenerative diseases.